[go: up one dir, main page]

WO2004071395A3 - Diagnostics and therapeutics for diseases associated with g protein-coupled receptor ox1r (ox1r) - Google Patents

Diagnostics and therapeutics for diseases associated with g protein-coupled receptor ox1r (ox1r) Download PDF

Info

Publication number
WO2004071395A3
WO2004071395A3 PCT/EP2004/000989 EP2004000989W WO2004071395A3 WO 2004071395 A3 WO2004071395 A3 WO 2004071395A3 EP 2004000989 W EP2004000989 W EP 2004000989W WO 2004071395 A3 WO2004071395 A3 WO 2004071395A3
Authority
WO
WIPO (PCT)
Prior art keywords
ox1r
diseases
therapeutics
diagnostics
protein
Prior art date
Application number
PCT/EP2004/000989
Other languages
French (fr)
Other versions
WO2004071395A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2004071395A2 publication Critical patent/WO2004071395A2/en
Publication of WO2004071395A3 publication Critical patent/WO2004071395A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human OX1R which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of OX1R as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/000989 2003-02-17 2004-02-04 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor ox1r (ox1r) WO2004071395A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003556 2003-02-17
EP03003556.2 2003-02-17

Publications (2)

Publication Number Publication Date
WO2004071395A2 WO2004071395A2 (en) 2004-08-26
WO2004071395A3 true WO2004071395A3 (en) 2005-03-03

Family

ID=32864947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/000989 WO2004071395A2 (en) 2003-02-17 2004-02-04 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor ox1r (ox1r)

Country Status (1)

Country Link
WO (1) WO2004071395A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0849361A2 (en) * 1996-12-17 1998-06-24 Smithkline Beecham Corporation Novel ligands of the neuropeptide receptor HFGAN72
WO1999030670A2 (en) * 1997-12-15 1999-06-24 Smithkline Beecham Plc Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
WO2001000787A2 (en) * 1999-06-25 2001-01-04 Smithkline Beecham Corporation Methods of treatment using lig 72a and variants thereof
WO2001014555A1 (en) * 1999-08-23 2001-03-01 Decode Genetics Ehf. Human narcolepsy gene
US20010025031A1 (en) * 1998-06-08 2001-09-27 Ellis Catherine E. HFGAN72 receptor genomic DNA, variants thereof, and methods of use thereof in diagnostic applications
US20030022277A1 (en) * 1995-05-05 2003-01-30 Daniel R. Soppet Human neuropeptide receptor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022277A1 (en) * 1995-05-05 2003-01-30 Daniel R. Soppet Human neuropeptide receptor
EP0849361A2 (en) * 1996-12-17 1998-06-24 Smithkline Beecham Corporation Novel ligands of the neuropeptide receptor HFGAN72
WO1999030670A2 (en) * 1997-12-15 1999-06-24 Smithkline Beecham Plc Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
US20010025031A1 (en) * 1998-06-08 2001-09-27 Ellis Catherine E. HFGAN72 receptor genomic DNA, variants thereof, and methods of use thereof in diagnostic applications
WO2001000787A2 (en) * 1999-06-25 2001-01-04 Smithkline Beecham Corporation Methods of treatment using lig 72a and variants thereof
WO2001014555A1 (en) * 1999-08-23 2001-03-01 Decode Genetics Ehf. Human narcolepsy gene

Also Published As

Publication number Publication date
WO2004071395A2 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
WO2004097421A3 (en) Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
WO2004042389A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
WO2003093816A3 (en) Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
WO2004008153A3 (en) Diagnostics and therapeutics for diseases associated with homo sapiens putative neurotransmitter receptor (pnr)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2004042402A3 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2005095972A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor etb (etb)
WO2003065044A8 (en) Diagnostics and therapeutics for diseases associated with gpr72
WO2004071395A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor ox1r (ox1r)
WO2003095967A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2003100433A3 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)
WO2003066077A3 (en) Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
WO2004071394A3 (en) Diagnostics and therapeutics for diseases associated with hm74
WO2003083135A3 (en) Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
WO2003100435A3 (en) Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2)
WO2004038406A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 42 (gpr42)
WO2004072651A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 1f receptor (5-ht1f)
WO2004057328A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor 38 (gpr38)
WO2004015427A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
WO2003081257A3 (en) Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 1 (npff1)
WO2004042405A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase